Skip to main content
Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
Excellent questions. I haven't been able to find information on the manner of the swab test. I'd guess that if it was self-swab, Veracyte and JNJ would be talking that up. So it is likely that a physician must administer.

Agreed on possible obstacles to uptake. Veracyte doesn't compare to GH or EXAS in reach or ambition; their growth is rapid and priced accordingly. Veracyte's appeal was that it may be on the precipice of moving into bigger markets. But I may have been mistaken.

In the course of learning more about the test, I found additional material that adds important nuance to the claim of the swab test expanding TAM. Apparently, the $30b number is the overall global lung cancer diagnostic market. The swab test under development has a market opportunity of nearer to $1.9b in the U.S. and $3.9 in the U.S. and E.U. That changes the entire conversation and makes the company much less interesting- it remains a niche firm for now.
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.